Cost-effectiveness of catheter ablation in end-stage heart failure with atrial fibrillation: Insights from CASTLE-HTx
Heart Rhythm · 2026
DOI: 10.1016/j.hrthm.2026.05.024 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Heart Rhythm, 2026. Verfasst von Priyanka Boettger und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology and Critical Care Medicine, Justus Liebig University of Giessen, Giessen, Germany; Department of Health Policy, L…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Heart Failure, Heart Transplantation. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Von-Behring-Röntgen-Stiftung, Deutsche Herzstiftung, Else Kröner Fresenius Foundation.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: The CASTLE-HTx (Catheter Ablation for Atrial Fibrillation in patientS With End-sTage Heart Failure and Eligibility for Heart Transplantation; ClinicalTrials.gov identifier NCT04649801) trial showed that the combination of catheter ablation and guideline-directed medical therapy (GDMT) was associated with a lower likelihood of a composite of death from any cause, implantation of a left ventricular assist device, or heart transplantation (HTx) in patients with end-stage heart failure (HF) and atrial fibrillation (AF). OBJECTIVE: This analysis evaluates the cost-effectiveness of catheter ablation plus GDMT vs medical therapy alone in patients with end-stage HF and AF referred for HTx evaluation. METHODS: In CASTLE-HTx, we randomized 194 patients in end-stage HF and AF to receive catheter ablation and GDMT (n = 97) or medical therapy alone (n = 97). Details of study design, outcome definitions, and results have been published. A cohort-based Markov model projected lifetime costs, life-years (LYs), and quality-adjusted life-years (QALYs) from the perspective of the German statutory health insurance system using 3-year outcomes from CASTLE-HTx. RESULTS: In lifetime projections, the combination of AF ablation and GDMT was associated with a mean survival gain of ∼1.7 LYs per patient at an incremental cost of ∼€12,000, yielding an incremental cost-effectiveness ratio of ∼€7300 per LY gained. The incremental cost-effectiveness ratios per QALY in lifetime projections (€8600) and at 36 months (€30,400) were below €50,000 per QALY, indicating cost-effectiveness at contemporary thresholds. Within 36 months, this survival benefit resulted in a gain of 0.34 LYs, reflecting prevention of death and worsening HF. The long-term benefit emerged early and remained consistent across sensitivity analyses. CONCLUSION: The combination of catheter ablation and GDMT is cost-effective and economically favorable in patients with end-stage HF and AF who are referred for HTx evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Angiology and Critical Care Medicine, Justus Liebig University of Giessen, Giessen, Germany; Department of Health Policy, London School of Economics and Political Science, London, United Kingdo…
- Department of Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany; Cardiology Department, Tulane University School of Medicine, New Orleans, Louisiana.
- Department of Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
- Cardiology Department, Tulane University School of Medicine, New Orleans, Louisiana.
- Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Med. Fakultät OWL (Universität Bielefeld), Bad Oeynhausen, Germany; Heart Failure Department, Herz- und Diabeteszen…
- Department of Cardiology and CARIM, Maastricht University, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
Förderung
- Von-Behring-Röntgen-Stiftung
- Deutsche Herzstiftung
- Else Kröner Fresenius Foundation
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Boettger, P., Moersdorf, M., Sommer, P., Marrouche, N. F., Costard-Jaeckle, A., Crijns, H. J. G. M., Bergau, L., Fox, H., Hindricks, G., Dagres, N., Schramm, R., Fink, T., Khalaph, M., Sciacca, V., Didenko, M., Konietschke, F., Rudolph, V., Gummert, J., Tijssen, J. G. P., …, & CASTLE HTx Investigators (2026). Cost-effectiveness of catheter ablation in end-stage heart failure with atrial fibrillation: Insights from CASTLE-HTx. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2026.05.024
Vancouver
Boettger P, Moersdorf M, Sommer P, Marrouche NF, Costard-Jaeckle A, Crijns HJGM, et al. Cost-effectiveness of catheter ablation in end-stage heart failure with atrial fibrillation: Insights from CASTLE-HTx. Heart Rhythm. 2026. doi:10.1016/j.hrthm.2026.05.024
BibTeX
@article{Boettger2026,
author = {Boettger, Priyanka and Moersdorf, Maximilian and Sommer, Philipp and Marrouche, Nassir F and Costard-Jaeckle, Angelika and Crijns, Harry J G M and Bergau, Leonard and Fox, Henrik and Hindricks, Gerhard and Dagres, Nikolaos and Schramm, Rene and Fink, Thomas and Khalaph, Moneeb and Sciacca, Vanessa and Didenko, Maxim and Konietschke, Frank and Rudolph, Volker and Gummert, Jan and Tijssen, Jan G P and Sossalla, Samuel and Sohns, Christian and CASTLE HTx Investigators, CASTLE HTx Investigators},
title = {Cost-effectiveness of catheter ablation in end-stage heart failure with atrial fibrillation: Insights from CASTLE-HTx},
journal = {Heart Rhythm},
year = {2026},
doi = {10.1016/j.hrthm.2026.05.024}
}
EUVIMED